[
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
    "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years […]",
    "url": "https://finnhub.io/api/news?id=d051e5c002daed3e494ec99eff3fad48ee990cf7bf7fa8b799fbcec10a11cc3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743377108,
      "headline": "AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
      "id": 133622662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years […]",
      "url": "https://finnhub.io/api/news?id=d051e5c002daed3e494ec99eff3fad48ee990cf7bf7fa8b799fbcec10a11cc3b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
    "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
    "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743310800,
      "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
      "id": 133598030,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
      "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    }
  }
]